Low-grade glioma (from which IDH-mutated GBM could arise) was included in the analysis to determine whether WWOX loss might also switch expression profile at the earlier stages of carcinogenesis; this may potentially lead to an improved on-time diagnosis. The gene discussed is WWOX; the disease is central nervous system cancer.